ArticleScientific reports2026
Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research has shown medical cannabis (MC) to help reduce anxiety for some individuals, although most studies show trends using cross-sectional designs or conduct secondary analyses of preexisting data. The present study systematically tracked 416 registered MC patients in Florida across 45 days to assess daily shifts in anxiety levels. Using daily recording software, collected data included the frequency of MC use, other substances (e.g., alcohol, anxiolytic medication), other activities (e.g., exercise, meditation), length of previous MC use, and history of anxiety, among other demographic variables. Using linear mixed-effects modeling, results showed that MC use led to the largest anxiety relief across the 45-day period. When participants only used other substances or engaged in activities on certain days, they also saw anxiety reductions, but the major factor in any measurable change in anxiety when comparing different groups to one another was MC use. Age, sex, history of MC use, length of anxiety, and route of MC administration did not significantly contribute to the findings. Sensitivity analyses revealed that novice and experienced MC patients had similar anxiety reductions, although novice patients had slightly better relief outcomes than experienced patients across the 45 days. The anxiolytic effects of MC documented in this study comport with other published work conducting secondary analyses of preexisting data. Although MC can have anxiogenic effects in some individuals, others find it to be an effective way to reduce daily anxiety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.